A recent study in the Journal of the American Society of Nephrology, led by the Libin Cardiovascular Institute of Alberta‘s Dr. Ellen Burgess, is generating international attention!
Excerpt from the Press Release:
Taking a much higher than recommended dose of the hypertension drug candesartan cilexetil effectively lowered the amount of protein excreted in the urine of patients with kidney disease, according to a study appearing in the April 2009 issue of the Journal of the American Society Nephrology (JASN). By reducing such proteinuria, the drug could potentially prevent the development of serious complications such as end-stage kidney disease and therefore save many patients’ lives.
Many research efforts are focused on finding ways to lower urinary protein excretion in patients with kidney disease because doing so may postpone kidney failure and prevent the development of cardiovascular disease.
To read the entire Press Release Click Here
To read a related article by the Washington Bureau of Reuters Click Here
To read the JASN abstract Click Here